Skip to content
2000
  1. Home
  2. A-Z Publications
  3. The International Journal of Gastroenterology and Hepatology Diseases
  4. Volume 3, Issue 1
  5. Article
Volume 3, Issue 1
  • ISSN: 2666-2906
  • E-ISSN: 2666-2914

Abstract

Introduction

Pantoprazole is a very suitable drug for the treatment of numerous acid-related conditions in humans and mammals. Owing to its short half-life (0.9 - 1.9 h), it is ideal for sustained release formulation.

Methods

This study was aimed at developing pantoprazole gastroretentive (GR) controlled-release tablets and to determine the effects of this formulation and processing parameters on drug release and other critical quality attributes of directly compressed tablets produced using different matrix-forming polymers, namely, Hydroxypropyl methylcellulose (HPMC), chitosan, sodium alginate, maize starch, kappa- carrageenan, and propyl vinyl pyrrolidine PVP K-30 when formulated into effervescent Floating Drug Delivery Systems (FDDS).

Results

The buoyancy lag time of less than 5 seconds and a total floating time of more than 12 hours for all batches is a good indication of achieved floatation for FDDS.

Conclusion

Validation processes initiated with the five batches indicated that the polymer blends had the potential for the formulation of pantoprazole FDDS and, hence, could enhance patient compliance and better treatment outcomes due to their sustained release potentials.

© 2024 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/ijghd/10.2174/0126662906296242240603104029
2024-06-25
2025-06-20

  • From This Site

    /content/journals/ijghd/10.2174/0126662906296242240603104029
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. NHSinformStomach ulcers.Available From https://www.nhsinform.scot/illnesses-and-conditions/stomach-liver-and-gastrointestinal-tract/stomach-ulcer/ (Accessed on 8th November, 2023.)
     [Google Scholar]
  2. SverdénE. AgréusL. DunnJ.M. LagergrenJ. Peptic ulcer disease.BMJ2019367l549510.1136/bmj.l5495 31578179
     [Google Scholar]
  3. LanasA. ChanF.K.L. Peptic ulcer disease.Lancet20173901009461362410.1016/S0140‑6736(16)32404‑7 28242110
     [Google Scholar]
  4. XieX. RenK. ZhouZ. DangC. ZhangH. The global, regional and national burden of peptic ulcer disease from 1990 to 2019: A population-based study.BMC Gastroenterol.20222215810.1186/s12876‑022‑02130‑2 35144540
     [Google Scholar]
  5. RosenstockS.J. JørgensenT. Prevalence and incidence of peptic ulcer disease in a Danish County--a prospective cohort study.Gut199536681982410.1136/gut.36.6.819 7615266
     [Google Scholar]
  6. GralnekI. DumonceauJ.M. KuipersE. LanasA. SandersD. KurienM. RotondanoG. HuclT. Dinis-RibeiroM. MarmoR. RaczI. ArezzoA. HoffmannR.T. LesurG. de FranchisR. AabakkenL. VeitchA. RadaelliF. SalgueiroP. CardosoR. MaiaL. ZulloA. CipollettaL. HassanC. Diagnosis and management of nonvariceal upper gastrointestinal hemorrhage: European Society of Gastrointestinal Endoscopy (ESGE) Guideline.Endoscopy20154710a1a4610.1055/s‑0034‑1393172 26417980
     [Google Scholar]
  7. DallM. Schaffalitzky de MuckadellO.B. LassenA.T. HallasJ. There is an association between selective serotonin reuptake inhibitor use and uncomplicated peptic ulcers: A population‐based case-control study.Aliment. Pharmacol. Ther.20103211-121383139110.1111/j.1365‑2036.2010.04472.x 21050241
     [Google Scholar]
  8. KragM. PernerA. WetterslevJ. WiseM.P. BorthwickM. BendelS. McArthurC. CookD. NielsenN. PelosiP. KeusF. GuttormsenA.B. MollerA.D. MøllerM.H. Prevalence and outcome of gastrointestinal bleeding and use of acid suppressants in acutely ill adult intensive care patients.Intensive Care Med.201541583384510.1007/s00134‑015‑3725‑1 25860444
     [Google Scholar]
  9. LauJ.Y. SungJ. HillC. HendersonC. HowdenC.W. MetzD.C. Systematic review of the epidemiology of complicated peptic ulcer disease: Incidence, recurrence, risk factors and mortality.Digestion201184210211310.1159/000323958 21494041
     [Google Scholar]
  10. JungnickelP.W. A new proton pump inhibitor, in new drugs.Clin. Ther.2000221112681293
     [Google Scholar]
  11. WelageL.S. BerardiR.R. Evaluation of omeprazole, lansoprazole, pantoprazole, and rabeprazole in the treatment of acidrelated diseases.J. Am. Pharm. Assoc.200040140524062
     [Google Scholar]
  12. RichardsonP. HawkeyC.J. StackW.A. Proton pump inhibitors. Pharmacology and rationale for use in gastrointestinal disorders.Drugs199856330733510.2165/00003495‑199856030‑00002 9777309
     [Google Scholar]
  13. PallottaS. PaceF. MarelliS. Rabeprazole: A second-generation proton pump inhibitor in the treatment of acid-related disease.Expert Rev. Gastroenterol. Hepatol.20082450952210.1586/17474124.2.4.509 19072398
     [Google Scholar]
  14. TytgatG.N. Shortcomings of the first-generation proton pump inhibitors.Eur. J. Gastroenterol. Hepatol.200113Suppl. 1S29S33 11430506
     [Google Scholar]
  15. KromerW. Similarities and differences in the properties of substituted benzimidazoles: A comparison between pantoprazole and related compounds.Digestion199556644345410.1159/000201275 8536813
     [Google Scholar]
  16. AnkaluD. NandhakumarS. DevalaraoG. Delayed release formulation of pantoprazole using sureteric aqueous dispersion system.Pharm. Lett.201355175186
     [Google Scholar]
  17. ShinJ.M. BesanconM. PrinzC. Continuing development of acid pump inhibitors: Site of action of pantoprazole.Aliment. Pharmacol. Ther.19948Suppl. 11123
     [Google Scholar]
  18. SachsG. Proton pump inhibitors and acid-related diseases.Pharmacotherapy1997171223710.1002/j.1875‑9114.1997.tb03675.x 9017763
     [Google Scholar]
  19. SachsG. PrinzC. LooD. BambergK. BesanconM. ShinJ.M. Gastric acid secretion: Activation and inhibition.Yale J. Biol. Med.1994673-48195 7502535
     [Google Scholar]
  20. FittonA. WisemanL. Pantoprazole.Drugs199651346048210.2165/00003495‑199651030‑00012 8882382
     [Google Scholar]
  21. HuberR KohlB SachsG Review article: The continuing development of proton pump inhibitors with particular reference to pantoprazole.Aliment Pharmaco1 Ther19959363378
     [Google Scholar]
  22. SimonB. MüllerP. BliesathH. LühmannR. HartmannM. HuberR. WurstW. Single intravenous administration of the H +, K + ‐ATPase inhibitor BY 1023/SK&F 96022—inhibition of pentagastrin‐stimulated gastric acid secretion and pharmacokinetics in man.Aliment. Pharmacol. Ther.19904323924510.1111/j.1365‑2036.1990.tb00468.x 1966542
     [Google Scholar]
  23. SimonB. MullerP. HartmannM. Pentagastrin- stimulated gastric acid secretion and pharmacokinetics following single and repeated intravenous administration of the gastric H+,K+-ATPase-inhibitor pantoprazole (BY 1023/SK&F%O22) in healthy vohmteets.Z. Gastroenterol.1990289443447
     [Google Scholar]
  24. HannanA. WeilJ. BroomC. WaltR.P. Effects of oral pantoprazole on 24‐hour intragastric acidity and plasma gastrin profiles.Aliment. Pharmacol. Ther.19926337338010.1111/j.1365‑2036.1992.tb00058.x 1600053
     [Google Scholar]
  25. KoopH. KulyS. FlügM. EisseleR. MönnikesH. RoseK. LühmannR. SchneiderA. FischerR. ArnoldR. Intragastric pH and serum gastrin during administration of different doses of pantoprazole in healthy subjects.Eur. J. Gastroenterol. Hepatol.199689915918 8889461
     [Google Scholar]
  26. MössnerJ. HölscherA.H. HerzR. SchneiderA. A double‐blind study of pantoprazole and omeprazole in the treatment of reflux oesophagitis: A multicentre trial.Aliment. Pharmacol. Ther.19959332132610.1111/j.1365‑2036.1995.tb00388.x 7654895
     [Google Scholar]
  27. EscourrouJ. DeprezP. SaggioroA. GeldofH. FischerR. MaierC. Maintenance therapy with pantoprazole 20 mg prevents relapse of reflux oesophagitis.Aliment. Pharmacol. Ther.199913111481149110.1046/j.1365‑2036.1999.00651.x 10571605
     [Google Scholar]
  28. AnderssonT. Pharmacokinetics, metabolism and interactions of acid pump inhibitors. Focus on omeprazole, lansoprazole and pantoprazole.Clin. Pharmacokinet.199631192810.2165/00003088‑199631010‑00002 8827397
     [Google Scholar]
  29. HuberR. HartmannM. BliesathH. LühmannR. SteinijansV.W. ZechK. Pharmacokinetics of pantoprazole in man.Int. J. Clin. Pharmacol. Ther.1996345185194 8738854
     [Google Scholar]
  30. TanakaM. YamazakiH. RyokawaY. HakusuiH. NakamichiN. SekinoH. Pharmacokinetics and tolerance of pantoprazole, a proton pump inhibitor after single and multiple oral doses in healthy Japanese volunteers.Int. J. Clin. Pharmacol. Ther.19963410415419 8897077
     [Google Scholar]
  31. PueM.A. LarocheJ. MeinekeI. de MeyC. Pharmacokinetics of pantoprazole following single intravenous and oral administration to healthy male subjects.Eur. J. Clin. Pharmacol.199344657557810.1007/BF02440862 8405016
     [Google Scholar]
  32. WitzelL. GützH. HüttemannW. ScheppW. Pantoprazole versus omeprazole in the treatment of acute gastric ulcers.Aliment. Pharmacol. Ther.199591192410.1111/j.1365‑2036.1995.tb00346.x 7766739
     [Google Scholar]
  33. HotzJ. PleinK. SchonekasH. RoseK. Pantoprazole is superior to ranitidine in the treatment of acute gastric ulcer.Stand. J. Gastroenterol.199530111115
     [Google Scholar]
  34. PatelS.S. RayS. ThakurR.S. Formualtion and evaluation of floating drug delivery system containing clarithromycin for Helicobacter pylori.Acta Pol. Pharm.20066315361
     [Google Scholar]
  35. GargS. SharmaS. Business Briefing Pharmatech200316066
     [Google Scholar]
  36. MayavanshiA.V. GajjarS.S. Floating drug delivery systems to increase gastric retention of drugs: A Review.Research J. Pharm. and Tech.200814345348
     [Google Scholar]
  37. LondheS. GattaniS. SuranaS. Development of floating drug delivery system with biphasic release for verapamil hydrochloride: In vitro and in vivo evaluation.J. Pharm. Sci. Technol.2010211361367
     [Google Scholar]
  38. HoffmanA. StepenskyD. LavyE. EyalS. KlausnerE. FriedmanM. Pharmacokinetic and pharmacodynamic aspects of gastroretentive dosage forms.Int. J. Pharm.20042771-214115310.1016/j.ijpharm.2003.09.047 15158977
     [Google Scholar]
  39. TalukderR. FassihiR. Gastroretentive delivery systems: A mini review.Drug Dev. Ind. Pharm.200430101019102810.1081/DDC‑200040239 15595568
     [Google Scholar]
  40. JaiminiM. RanaA. TanwarY. Formulation and evaluation of famotidine floating tablets.Curr. Drug Deliv.200741515510.2174/156720107779314730 17269917
     [Google Scholar]
  41. AliJ. AroraS. AhujaA. BabbarA.K. SharmaR.K. KharR.K. BabootaS. Formulation and development of hydrodynamically balanced system for metformin: in vitro and in vivo evaluation.Eur. J. Pharm. Biopharm.200767119620110.1016/j.ejpb.2006.12.015 17270409
     [Google Scholar]
  42. VarshosazJ. TavakoliN. RoozbahaniF. Formulation and in vitro characterization of ciprofloxacin floating and bioadhesive extended-release tablets.Drug Deliv.200613427728510.1080/10717540500395106 16766469
     [Google Scholar]
  43. MaggiL. MachisteE.O. TorreM.L. ConteU. Formulation of biphasic release tablets containing slightly soluble drugs.Eur. J. Pharm. Biopharm.1999481374210.1016/S0939‑6411(99)00019‑3 10477326
     [Google Scholar]
  44. SinghB. KimK.H. Floating drug delivery systems: An approach to oral controlled drug delivery via gastric retention.J. Control. Release200063323525910.1016/S0168‑3659(99)00204‑7 10601721
     [Google Scholar]
  45. KimC.J. Dosage Form Design.LancasterTechnomic Pub2000
     [Google Scholar]
  46. ChimeS.A. KenechukwuF.C. OnunkwoG.C. AttamaA.A. OgbonnaJ.D. Micromeritic and antinociceptive properties of lyophilized indomethacin loaded SLMs based on solidified reverse micellar solutions.J. Pharm. Res.20125634103416
     [Google Scholar]
  47. ChimeS. UmeyorE.C. OnyishiV.I. OnunkwoG.C. AttamaA.A. Analgesic and micromeritic evaluations of SRMS-based oral lipospheres of diclofenac potassium.Indian J. Pharm. Sci.201375330230910.4103/0250‑474X.117436 24082346
     [Google Scholar]
  48. OnyishiI.V. ChimeS.A. EgwuE. Application of ĸ-carrageenan as a sustained release matrix in floating tablets containing sodium salicylate.Afr. J. Pharm. Pharmacol.201373926672673
     [Google Scholar]
  49. HiguchiT. Rate of release of medicaments from ointment bases containing drugs in suspension.J. Pharm. Sci.1961501087487510.1002/jps.2600501018 13907269
     [Google Scholar]
  50. HiguchiT. Mechanism of sustained‐action medication. Theoretical analysis of rate of release of solid drugs dispersed in solid matrices.J. Pharm. Sci.196352121145114910.1002/jps.2600521210 14088963
     [Google Scholar]
  51. ChimeS.A. OnunkwoG.C. OnyishiI.V. Kinetics and mechanisms of drug release from swellable and non-swellable matrices: A review.Res. J. Pharm. Biol. Chem. Sci.20134297103
     [Google Scholar]
  52. RitgerP.L. PeppasN.A. A simple equation for description of solute release I. Fickian and non-fickian release from non-swellable devices in the form of slabs, spheres, cylinders or discs.J. Control. Release198751233610.1016/0168‑3659(87)90034‑4
     [Google Scholar]
  53. ShahR.B. TawakkulM.A. KhanM.A. Comparative evaluation of flow for pharmaceutical powders and granules.AAPS PharmSciTech20089125025810.1208/s12249‑008‑9046‑8 18446489
     [Google Scholar]
  54. CarrR.L. Evaluating flow properties of solids.Chem. Eng.1965726972
     [Google Scholar]
  55. ChimeS.A. OkekeJ.K. Comparative evaluation of Prosopis africana seed gum as a sustained release binder in colon targeted diclofenac potassium floating tablets.J. Curr. Pharma. Res.2015521411142410.33786/JCPR.2015.v05i02.005
     [Google Scholar]
  56. ChimeS.A. ObitteN.C. OnyishV.I. NwosuI.E. Development of cross-linked alginate beads by ionotropic gelation technique for controlled release of diclofenac sodium.Am. J. Pharm. Tech. Res.201335428437
     [Google Scholar]
  57. DesaiD. KothariS. HuangM. Solid-state interaction of stearic acid with povidone and its effect on dissolution stability of capsules.Int. J. Pharm.20083541-2778110.1016/j.ijpharm.2007.11.042 18194844
     [Google Scholar]
  58. SammourO.A. HammadM.A. MegrabN.A. ZidanA.S. Formulation and optimization of mouth dissolve tablets containing rofecoxib solid dispersion.AAPS PharmSciTech200672E167E17510.1208/pt070255 16796372
     [Google Scholar]
  59. ChimeS.A. AkpaP.A. UgwuanyiC.C. AttamaA.A. Anti-inflammatory and gastroprotective properties of aspirin - Entrapped solid lipid microparticles.Recent Pat. Inflamm. Allergy Drug Discov.2020141788810.2174/1872213X14666200108101548 31912772
     [Google Scholar]
  60. ThakkarV.T. ShahP.A. SoniT.G. ParmarM.Y. GohelM.C. GandhiT.R. Goodness-of-fit model-dependent approach for release kinetics of levofloxacin hemihydrates floating tablet.Dissolut. Technol.2009161353910.14227/DT160109P35
     [Google Scholar]
  61. AttamaA.A. NkemneleM.O. In vitro evaluation of drug release from self micro-emulsifying drug delivery systems using a biodegradable homolipid from Capra hircus.Int. J. Pharm.20053041-241010.1016/j.ijpharm.2005.08.018 16198521
     [Google Scholar]
  62. ChimeS. UgwuC.E. EjioforE.U. OnunkwoG.C. Application of Cyperus esculentus oil in the development of sustained release diclofenac sodium-loaded nanostructured lipid carrier.Journal of Current Biomedical Research202223, May-June14515910.54117/jcbr.v2i3.23
     [Google Scholar]
  63. GuguT.H. ChimeS.A. AttamaA.A. Solid lipid microparticles: An approach for improving oral bioavailability of aspirin. As.J. Pharm. Sci.2015105425432
     [Google Scholar]
  64. ChimeS.A. AttamaA.A. OnunkwoG.C. Assessment of the anti-malarial properties of dihydroartemisinin- piperaquine phosphate solid lipid-based tablets.Recent Adv. Antiinfect. Drug Discov.2022173103117
     [Google Scholar]
  65. MomohA.M. ChimeS.A. AnihC.V. OmehC.R. OgbonnaJ. NafiuA. OyeniyiY.J. AchorM. KenechukwuC.F. DavidD.D. A novel formulation design based on hetero-templated solid lipid microparticles to improve the solubility of anti-inflammatory piroxicam for oral administration.New J. Chem.202220224639613965
     [Google Scholar]
  66. NnamaniP.O. OgbonnaC.C. DibuaE.U. EzedigbohN.N. AttamaA.A. Sustained circulation time of glibenclamide from pegylated solid lipid microparticles.Int J Novel Drug Deliv Tech201222283290
     [Google Scholar]
  67. UmeyorE.C. KenechukwuF.C. OgbonnaJ.D. ChimeS.A. AttamaA. Preparation of novel solid lipid microparticles loaded with gentamicin and its evaluation in vitro and in vivo.J. Microencapsul.201229329630710.3109/02652048.2011.651495 22283701
     [Google Scholar]
  68. MomohM.A. AkpaP.A. Attama, AA Phospholipon 90G based SLMs loaded with ibuprofen: An oral antiinflammatory and gastro intestinal sparing evaluation in rats.Pak. J. Zool.165744616571664
     [Google Scholar]
  69. ChinaekeE.E. ChimeS.A. OnyishiI.V. AttamaA.A. OkoreV.C. Formu lation development and evaluation of the anti-malaria properties of sustained release artesunate-loaded solid lipid microparticles based on phytolipids.Drug Deliv.2014205546554 24479677
     [Google Scholar]
  70. ChinaekeE.E. ChimeS.A. KenechukwuF.C. Müller-GoymannC.C. AttamaA.A. OkoreV.C. Formulation of novel artesunate-loaded Solid Lipid Microparticles (SLMs) based on dika wax matrices: in vitro and in vivo evaluation.J. Drug Deliv. Sci. Technol.2014241697710.1016/S1773‑2247(14)50010‑X
     [Google Scholar]
  71. AttamaA.A. OkaforC.E. BuildersP.F. OkorieO. Formulation and in vitro evaluation of a PEGylated microscopic lipospheres delivery system for ceftriaxone sodium.Drug Deliv.200916844845710.3109/10717540903334959 19839789
     [Google Scholar]
  72. ChimeS.A. AttamaA.A. BuildersP.F. OnunkwoG.C. Sustained-release diclofenac potassium-loaded solid lipid microparticle based on solidified reverse micellar solution: in vitro and in vivo evaluation.J. Microencapsul.201330433534510.3109/02652048.2012.726284 23057661
     [Google Scholar]
  73. ChinaekeE.E. ChimeS.A. OgbonnaJ.D.N. AttamaA.A. Müller-GoymannC.C. OkoreV.C. Evaluation of dika wax-soybean oil-based artesunate-loaded lipospheres: In vitro-in vivo correlation studies.J. Microencapsul.201431879680410.3109/02652048.2014.940008 25090593
     [Google Scholar]
  74. KenechukwuF.C. AttamaA.A. IbezimE.C. NnamaniP.O. UmeyorC.E. UronnachiE.M. MomohM.A. AkpaP.A. OziokoA.C. Novel intravaginal drug delivery system based on molecularly pegylated lipid matrices for improved antifungal activity of miconazole nitrate.BioMed Res. Int.2018201811810.1155/2018/3714329 29977910
     [Google Scholar]
/content/journals/ijghd/10.2174/0126662906296242240603104029
Loading
Development and In vitro Evaluation of Pantoprazole-Sustained Release Effervescent Floating Tablets for Effective Management of Ulcer
Int J Gastroenterol Hepatol Dis 3, E250624231309 (2024); https://doi.org/10.2174/0126662906296242240603104029
/content/journals/ijghd/10.2174/0126662906296242240603104029
/content/journals/ijghd/10.2174/0126662906296242240603104029
Loading

Data & Media loading...


  • Article Type:     Research Article
Keyword(s): Buoyancy lag time; controlled release tablets; floating tablets; gastro-retentive drug delivery- effervescence tablets; k-carrageenan; pantoprazole; proton pump inhibitors; ulcer

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test